Vanguard Fiduciary Trust
KYMR icon

Vanguard Fiduciary Trust’s Kymera Therapeutics KYMR Stock Holding History

Vanguard Fiduciary Trust’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.6M Buy
449,731
+22,349
+5% +$1.92M 0.01% 848
2026
Q1 		$35.6M Buy
+427,382
New +$33.8M 0.01% 980

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Fiduciary Trust's KYMR Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Kymera Therapeutics (KYMR) stake by 5.2% in Q2 2026, buying an estimated $1.92M and bringing the position to 449,731 shares worth $51.6M. The position accounts for 0.01% of the portfolio, ranked #848.

Vanguard Fiduciary Trust first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 273 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Vanguard Fiduciary Trust held 449,731 shares of Kymera Therapeutics worth $51.6M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 22,349 Kymera Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Kymera Therapeutics made up 0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #848 holding.
  • Vanguard Fiduciary Trust first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 273 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.